30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

SI-BONE Files for Proposed IPO -

SI-BONE publicly filed a registration statement for a proposed initial public offering of shares of its common stock, and applied to list on NASDAQ as SIBN. The number of shares and price range are not yet determined. Proceeds will primarily support commercialization activities. The company markets iFuse and iFuse-3D minimally invasive surgical implant systems for the treatment of sacroiliac joint dysfunction. Since launch in 2009, >34,000 procedures have been performed by >1,700 surgeons globally. For 2017, the company posted revenue of US $48.0MM, +14.0% from 2016. (SI-BONE, Inc., 9/20/18)